Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07389525 · ClinicalTrials.gov registry record · Early Phase 1
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
A Early Phase 1 study, sponsored by Indiana University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
NCT07389525: Clinical Trial Early Phase 1 study, sponsored by Indiana University.
NCT07389525 is a Early Phase 1 study that has not yet begun recruiting, run by Indiana University. The registered enrollment target is 80 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07389525, a Early Phase 1 study, has not yet begun recruiting, sponsored by Indiana University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs work differently, or causing more side effects. The purpose of this study is to see whether ICIs impact how the liver processes other drugs. To do this, participants will be given a probe cocktail of 7 different FDA-approved drugs that are processed in different ways in the liver.
Interventions
- DRUG ICI Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
What is known before NCT07389525 opens enrollment
NCT07389525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% higher).
The record links to 0 conditions, and to 1 intervention - of which ICI Therapy is the first listed.
NCT07389525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07389525 about?
NCT07389525 is a clinical study titled "Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study". Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some evidence suggests these side effects might happen because ICIs interact with other drugs that you may already be taking, making those drugs wo...
What is the current status of trial NCT07389525?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2026-06. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07389525?
The interventions under investigation include: ICI Therapy (DRUG).
Who is sponsoring clinical trial NCT07389525?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07389525's enrollment target sits among peer trials
80 271st of 2000 higher than 1,703 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia